Brief: Akari Therapeutics Reports Second Quarter 2022 Financial Results And Highlights Recent Pipeline Progress
27/09/2022 14:36
Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PIPELINE PROGRESS
* AKARI THERAPEUTICS - PHASE 3 PART A CLINICAL TRIAL OF IN
SEVERE
PEDIATRIC HSCT-TMA REMAINS ON TRACK FOR EXPECTED DATA READOUT IN
H1 OF 2023
Source text for Eikon: ID:nGNX6wl4F4
Further company coverage: AKTX.O
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics